Corneal Endothelial Dystrophy Pipeline Analysis & Clinical Trials, 2025, DelveInsight | Trefoil Therapeutics, Aerie Pharmaceuticals, Kowa Research Institute, Inc., Emmecell, Surrozen

DelveInsight's, "Corneal Endothelial Dystrophy - Pipeline Insight, 2025," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Corneal Endothelial Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, the Corneal Endothelial Dystrophy (CED) pipeline includes 4+ key companies actively developing more than 4 therapeutic candidates for CED treatment.

Corneal Endothelial Dystrophy Overview:

Corneal Endothelial Dystrophy (CED) refers to a group of disorders characterized by the gradual degeneration of the corneal endothelium, frequently influenced by genetic factors. This category includes congenital hereditary endothelial dystrophy types 1 and 2 (CHED1 and CHED2), posterior polymorphous corneal dystrophy (PPCD), and Fuchs endothelial corneal dystrophy (FECD). In all forms, progressive endothelial damage can result in severe vision loss or blindness, though the precise molecular mechanisms remain incompletely understood. Recent studies have begun to shed light on these processes and suggest a continuum among the different endothelial dystrophies. FECD is the most common type, marked by endothelial cell loss and the formation of excrescences on Descemet's membrane, frequently leading to significant visual impairment.

Download our report @ https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

"Corneal Endothelial Dystrophy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Corneal Endothelial Dystrophy Therapeutics Market.

Key Takeaways from the Corneal Endothelial Dystrophy Pipeline Report

*
DelveInsight's Corneal Endothelial Dystrophy (CED) pipeline report highlights an active landscape with 4+ companies developing more than 4 therapeutic candidates for CED treatment.

*
Design Therapeutics is advancing DT-168, a GeneTAC Trademark small-molecule eye drop targeting the CTG repeat expansion in the TCF4 gene, a known contributor to FECD. As of April 2025, Phase 1 trials in healthy volunteers have been completed, with Phase 2 trials in FECD patients planned.

*
In June 2024, Aurion Biotech's AURN001 received both Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation from the FDA. AURN001 is an allogeneic cell therapy combining neltependocel (cultured human corneal endothelial cells) with the ROCK inhibitor Y-27632, designed to treat corneal edema caused by endothelial dysfunction. This therapy offers a less invasive alternative to traditional corneal transplants. Aurion has completed enrollment in its Phase 1/2 CLARA trial conducted across the U.S. and Canada.

*
In March 2023, Japan's Pharmaceuticals and Medical Devices Agency approved this therapy, marketed as Vyznova, marking the first allogeneic cell therapy approved for corneal endothelial disease.

*
Other key players in the CED space include Trefoil Therapeutics, Aerie Pharmaceuticals, Kowa Research Institute, Inc., Emmecell, Surrozen, and more, all working to expand treatment options. Promising pipeline candidates include TTHX1114, Netarsudil mesylate, and others.

Corneal Endothelial Dystrophy Pipeline Analysis

The Corneal Endothelial Dystrophy pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Corneal Endothelial Dystrophy Market.

*
Categorizes Corneal Endothelial Dystrophy therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Corneal Endothelial Dystrophy drugs under development based on:

*
Stage of development

*
Corneal Endothelial Dystrophy Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Corneal Endothelial Dystrophy Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Corneal Endothelial Dystrophy Licensing agreements

*
Funding and investment activities supporting future Corneal Endothelial Dystrophy market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/corneal-endothelial-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Corneal Endothelial Dystrophy Emerging Drugs

*
TTHX1114: Trefoil Therapeutics

TTHX1114 is a proprietary, engineered form of Fibroblast Growth Factor-1 (FGF-1), a naturally occurring protein that supports cell growth, migration, and protection against stress and injury. The molecule has been modified to extend its pharmacodynamic half-life, making it suitable for therapeutic applications. Preclinical studies indicate that TTHX1114 promotes endothelial cell proliferation and migration, facilitating regeneration of the corneal endothelial layer. It is currently undergoing Phase II development for the treatment of Corneal Endothelial Dystrophy.

*
Netarsudil mesylate: Aerie Pharmaceuticals

Netarsudil mesylate ophthalmic solution, developed by Aerie Pharmaceuticals under a license from Duke University Medical Center, is formulated to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension, and to alleviate or treat corneal edema linked to Fuchs' endothelial dystrophy.

Corneal Endothelial Dystrophy Companies

More than four leading companies are developing therapies for Corneal Endothelial Dystrophy (CED), with Trefoil Therapeutics at the forefront, advancing a candidate currently in Phase II development.

DelveInsight's report covers around 4+ products under different phases of Corneal Endothelial Dystrophy clinical trials like

*
Corneal Endothelial Dystrophy Late stage Therapies (Phase III)

*
Corneal Endothelial Dystrophy Mid-stage Therapies (Phase II)

*
Corneal Endothelial Dystrophy Early-stage Therapies (Phase I)

*
Corneal Endothelial Dystrophy Pre-clinical and Corneal Endothelial Dystrophy Discovery stage Therapies

*
Corneal Endothelial Dystrophy Discontinued & Inactive Therapies

Corneal Endothelial Dystrophy pipeline report provides the Corneal Endothelial Dystrophy therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Corneal Endothelial Dystrophy Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Corneal Endothelial Dystrophy Therapies and Key Corneal Endothelial Dystrophy Companies: Corneal Endothelial Dystrophy Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Corneal Endothelial Dystrophy Pipeline Therapeutic Assessment

- Corneal Endothelial Dystrophy Assessment by Product Type

- Corneal Endothelial Dystrophy By Stage

- Corneal Endothelial Dystrophy Assessment by Route of Administration

- Corneal Endothelial Dystrophy Assessment by Molecule Type

Download Corneal Endothelial Dystrophy Sample report to know in detail about the Corneal Endothelial Dystrophy treatment market @ Corneal Endothelial Dystrophy Therapeutic Assessment [https://www.delveinsight.com/sample-request/corneal-endothelial-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Corneal Endothelial Dystrophy Current Treatment Patterns

4. Corneal Endothelial Dystrophy - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Corneal Endothelial Dystrophy Late-Stage Products (Phase-III)

7. Corneal Endothelial Dystrophy Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Corneal Endothelial Dystrophy Discontinued Products

13. Corneal Endothelial Dystrophy Product Profiles

14. Corneal Endothelial Dystrophy Key Companies

15. Corneal Endothelial Dystrophy Key Products

16. Dormant and Discontinued Products

17. Corneal Endothelial Dystrophy Unmet Needs

18. Corneal Endothelial Dystrophy Future Perspectives

19. Corneal Endothelial Dystrophy Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Corneal Endothelial Dystrophy Pipeline Reports Offerings [https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=corneal-endothelial-dystrophy-pipeline-analysis-clinical-trials-2025-delveinsight-trefoil-therapeutics-aerie-pharmaceuticals-kowa-research-institute-inc-emmecell-surrozen]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.